Affimed (NASDAQ:AFMD) Share Price Passes Above 50-Day Moving Average - What's Next?

Affimed (NASDAQ:AFMD - Get Free Report) shares crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $3.54 and traded as high as $3.72. Affimed shares last traded at $3.66, with a volume of 196,860 shares traded.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on AFMD. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price target on shares of Affimed in a research note on Friday, September 6th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Affimed in a report on Monday, September 9th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $20.00.

Affimed Stock Down 2.5 %

The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.71 and a current ratio of 2.71. The company's 50-day moving average price is $3.54 and its two-hundred day moving average price is $4.59.

Affimed (NASDAQ:AFMD - Get Free Report) last announced its quarterly earnings data on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.00) by ($0.09). Affimed had a negative net margin of 2,922.74% and a negative return on equity of 155.30%. The business had revenue of $0.17 million during the quarter, compared to analyst estimates of $1.67 million. As a group, research analysts anticipate that Affimed will post -4.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Affimed stock. Choreo LLC acquired a new stake in shares of Affimed (NASDAQ:AFMD - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,000 shares of the biopharmaceutical company's stock, valued at approximately $54,000. Choreo LLC owned 0.07% of Affimed at the end of the most recent quarter. 30.82% of the stock is currently owned by hedge funds and other institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.